• 1
    Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321: 419-424.
  • 2
    Akaza H, Hinotsu S, Usami M, et al. Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009; 115: 3437-3445.
  • 3
    Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer [review]. BJU Int. 2004; 93: 1177-1182.
  • 4
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 1781-1788.
  • 5
    Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004; 171: 1141-1147.
  • 6
    [No authors listed] Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000; 355: 1491-1498.
  • 7
    Loblaw DA, Virgo KS, Nam R, et al; American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline [review]. J Clin Oncol. 2007; 20: 25: 1596-1605.
  • 8
    Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006; 24: 396-402.
  • 9
    Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2008 Oct 14. [Epub ahead of print].
  • 10
    Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer [review]. Future Oncol. 2006; 2: 677-696.
  • 11
    Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized,open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102: 1531-1538.
  • 12
    Moul JW, Wiederkehr D, Sendersky V, Connolly M, Stern L, Onel E. The influence of Medicare reform on the utilization of anti-androgens in a cohort of patients with prostate cancer in the United States. J Urol. 2008; 179(suppl): 30. Abstract 84.